Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lily L Remsing Rix

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Seminars in Cancer Biology|February 12, 2020
Turning liabilities into opportunities: Off-target based drug repurposing in cancerVinayak Palve, Yi Liao, Lily L Remsing Rix, et al.
Journal of the American Chemical Society|April 9, 2004
The dynamic structure of jadomycin B and the amino acid incorporation step of its biosynthesisUwe Rix, Jianting Zheng, Lily L Remsing Rix, et al.
ACS Chemical Biology|September 22, 2015
Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung CancerNatalia J Sumi, Brent M Kuenzi, Claire E Knezevic, et al.
Scientific Reports|January 26, 2019
Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemiaBrent M Kuenzi, Lily L Remsing Rix, Fumi Kinose, et al.
Proteomics|September 1, 2020
Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator ApproachBin Fang, Victoria Izumi, Lily L Remsing Rix, et al.
Chembiochem : a European Journal of Chemical Biology|March 19, 2005
The oxidative ring cleavage in jadomycin biosynthesis: a multistep oxygenation cascade in a biosynthetic black boxUwe Rix, Chenchen Wang, Yihua Chen, et al.
Molecular Cell|August 20, 2005
Structural basis for the cytoskeletal association of Bcr-Abl/c-AblOliver Hantschel, Silke Wiesner, Thomas Güttler, et al.
Cell Chemical Biology|October 17, 2023
Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2Yi Liao, Lily L Remsing Rix, Xueli Li, et al.
Nature Chemical Biology|October 10, 2017
Polypharmacology-based ceritinib repurposing using integrated functional proteomicsBrent M Kuenzi, Lily L Remsing Rix, Paul A Stewart, et al.
Molecular Oncology|November 8, 2017
Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibitionManali Phadke, Lily L Remsing Rix, Inna Smalley, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Seminars in Cancer Biology|February 12, 2020
Turning liabilities into opportunities: Off-target based drug repurposing in cancerVinayak Palve, Yi Liao, Lily L Remsing Rix, et al.
Journal of the American Chemical Society|April 9, 2004
The dynamic structure of jadomycin B and the amino acid incorporation step of its biosynthesisUwe Rix, Jianting Zheng, Lily L Remsing Rix, et al.
ACS Chemical Biology|September 22, 2015
Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung CancerNatalia J Sumi, Brent M Kuenzi, Claire E Knezevic, et al.
Scientific Reports|January 26, 2019
Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemiaBrent M Kuenzi, Lily L Remsing Rix, Fumi Kinose, et al.
Proteomics|September 1, 2020
Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator ApproachBin Fang, Victoria Izumi, Lily L Remsing Rix, et al.
Chembiochem : a European Journal of Chemical Biology|March 19, 2005
The oxidative ring cleavage in jadomycin biosynthesis: a multistep oxygenation cascade in a biosynthetic black boxUwe Rix, Chenchen Wang, Yihua Chen, et al.
Molecular Cell|August 20, 2005
Structural basis for the cytoskeletal association of Bcr-Abl/c-AblOliver Hantschel, Silke Wiesner, Thomas Güttler, et al.
Cell Chemical Biology|October 17, 2023
Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2Yi Liao, Lily L Remsing Rix, Xueli Li, et al.
Nature Chemical Biology|October 10, 2017
Polypharmacology-based ceritinib repurposing using integrated functional proteomicsBrent M Kuenzi, Lily L Remsing Rix, Paul A Stewart, et al.
Molecular Oncology|November 8, 2017
Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibitionManali Phadke, Lily L Remsing Rix, Inna Smalley, et al.
Pageof 3